Deciphera Shares Hit 2-Year High After $2.4 Billion Buyout Offer From ONO Pharma
By Chris Wack
Deciphera Pharmaceuticals shares hit a two-year high after receiving a buyout offer from ONO Pharmaceutical for $25.60 a share in cash, through a tender offer with a total equity value of $2.4 billion.
The stock was up 72% to $25.24 in early Monday trading, the highest it has been since November 2021.
Upon closing, Deciphera will be merged with a wholly-owned subsidiary of ONO. The boards of directors of both companies have unanimously approved the transaction.
The purchase price represents a premium of 74.7% to Deciphera's closing share price of $14.65 on Friday, and a premium of 68.8% to Deciphera's 30-trading-day volume weighted average price as of Friday.
The acquisition is expected to close in the third quarter of 2024.
Upon completion, Deciphera will operate as a standalone business of ONO Group, from its headquarters in Waltham, Mass.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 29, 2024 10:08 ET (14:08 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks
-
Real Estate: Performance Continues to Be Driven by Interest-Rate Movements
-
Financial Services: Sector Doing Well Heading Into Rate-Cutting Cycle
-
Energy: OPEC Faces Hard Supply Decision in Latter Half of 2024
-
This Cheap Stock Is Still a Buy Even After 50% Rally